While FGFR2’s role in endocrine resistance is established, its potential involvement in shaping immune infiltration—particularly in the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC)—remains underexplored. Here, FGFR2 is linked to ductal breast carcinoma in situ.